Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $57.80 | Total: $289.00 |
| 1 | 10 | $48.96 | Total: $489.60 |
| 1 | 25 | $41.48 | Total: $1,037.00 |
| 1 | 50 | $35.36 | Total: $1,768.00 |
| 1 | 100 | $30.60 | Total: $3,060.00 |
Overview
Histrelin acetate is a nonapeptide analog of gonadotropin-releasing hormone (GnRH) with added potency. It acts on particular cells of the pituitary gland called gonadotropes when present in the bloodstream. Histrelin stimulates these cells to release luteinizing hormone and follicle-stimulating hormone. Thus it is considered a gonadotropin-releasing hormone agonist or GnRH agonist.
Chemical Properties
| Molecular Formula | C68H90N18O14 |
| Molecular Weight | 1383.55 |
| CAS Numbers | 220810-26-4 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CCNC([C@@H]1CCCN1C([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@@H](CC2=CN(C=N2)CC3=CC=CC=C3)NC([C@H](CC4=CC=C(C=C4)O)NC([C@H](CO)NC([C@H](CC5=CNC6=CC=CC=C65)NC([C@H](CC7=CNC=N7)NC([C@@H]8CCC(N8)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.CC(O)=O |
Storage and Handling
0C Short Term, -20C Long Term
References
Crawford ED. A review of the use of histrelin acetate in the treatment of prostate cancer. BJU Int. 2009 Mar;103 Suppl 2 14-22.